convertible
Sarepta Extends $700M Debt to 2030, Adds Private Placement Amid Elevidys Uncertainty
Sarepta Therapeutics; debt maturity extension; convertible notes; private placement; Elevidys; financial strategy; biopharma
Actionable Insights Powered by AI
Sarepta Therapeutics; debt maturity extension; convertible notes; private placement; Elevidys; financial strategy; biopharma